Counts and Characteristics of Individuals with Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitor Use: A Descriptive Analysis

Basic Details
Date Posted
Friday, July 15, 2022
Status
Complete
Medical Product
sodium-glucose co-transporter-2 (SGLT-2) inhibitor
Description

In this report, we examined counts of individuals with sodium-glucose co-transporter-2 (SGLT-2) inhibitor and sitagliptin dispensings in the Sentinel Distributed Database (SDD) along with baseline conditions and other medication use. The study period includes data from March 1, 2013 to June 30, 2018. We distributed this request to six Sentinel Data Partners on September 21, 2021.

Deliverables (1)
Sentinel Modular Program Report: Counts and Characteristics of Individuals with Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitor Use: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
March 1, 2013 - June 30, 2018
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Individuals aged 20 and older
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Analysis: Characterization of SGLT-2 Inhibitor Users in the Patient-Centered Clinical Research Network (PCORnet)
Characteristics of Patients Using Anti-Diabetic Agents in the Patient-Centered Clinical Research Network (PCORnet): An Exploratory Query of a Network of Electronic Health Records